a b s t r a c t
Decreased activity of catechol-O-methyltransferase (COMT), an enzyme that metabolizes catecholamines, contributes to pain in humans and animals. Previously, we demonstrated that development of COMT-dependent pain is mediated by both b 2 -and b 3 -adrenergic receptors (b 2 ARs and b 3 ARs). Here we investigated molecules downstream of b 2 -and b 3 ARs driving pain in animals with decreased COMT activity. Based on evidence linking their role in pain and synthesis downstream of b 2 -and b 3 AR stimulation, we hypothesized that nitric oxide (NO) and proinflammatory cytokines drive COMT-dependent pain. To test this, we measured plasma NO derivatives and cytokines in rats receiving the COMT inhibitor OR486 in the presence or absence of the b 2 AR antagonist ICI118,551 + b 3 AR antagonist SR59320A. We also assessed whether the NO synthase inhibitor L-N G -nitroarginine methyl ester (L-NAME) and cytokine-neutralizing antibodies block the development of COMT-dependent pain. Results showed that animals receiving OR486 exhibited higher levels of NO derivatives, tumor necrosis factor a (TNFa), interleukin-1b (IL-1b), interleukin-6 (IL-6), and chemokine (C-C motif) ligand 2 (CCL2) in a b 2 -and b 3 AR-dependent manner. Additionally, inhibition of NO synthases and neutralization of the innate immunity cytokines TNFa, IL-1b, and IL-6 blocked the development of COMT-dependent pain. Finally, we found that NO influences TNFa, IL-1b, IL-6, and CCL2 levels, whereas TNFa and IL-6 influence NO levels. Altogether, these results demonstrate that b 2 -and b 3 ARs contribute to COMT-dependent pain, at least partly, by increasing NO and cytokines. Furthermore, they identify b 2 -and b 3 ARs, NO, and proinflammatory cytokines as potential therapeutic targets for pain patients with abnormalities in COMT physiology.
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Introduction
A growing literature demonstrates that catecholamines and pathways regulating their bioavailability influence pain. Patients with chronic pain conditions, including fibromyalgia and temporomandibular disorders (TMD), exhibit increased levels of the catecholamines epinephrine and norepinephrine [19, 45, 69, 78] and decreased levels of the enzyme catechol-O-methyltransferase (COMT) [16, 26, 80] , which metabolizes epinephrine and norepinephrine [49] . Consistent with these findings, animal studies show that epinephrine administration [11, 36, 37] or COMT inhibition [34, 52] [1, 7, [21] [22] [23] 28, 48, 74, 76] .
Nitric oxide is a gaseous molecule whose production by NO synthases can be induced by stimulation of b 2 ARs on endothelial cells, smooth muscle, sympathetic afferent neurons, and macrophages [1, 21, 28] 
